| 1.79 0.01 (0.56%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.67  |
1-year : | 4.87 |
| Resists | First : | 3.15 |
Second : | 4.17 |
| Pivot price | 2.38  |
|||
| Supports | First : | 1.5 |
Second : | 1.24 |
| MAs | MA(5) : | 2 |
MA(20) : | 2.51 |
| MA(100) : | 1.73 |
MA(250) : | 2.68 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 4.3 |
D(3) : | 3.4 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 10.19 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BJDX ] has closed above bottom band by 12.4%. Bollinger Bands are 124.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 20 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.75 - 1.77 | 1.77 - 1.78 |
| Close: | 1.77 - 1.79 | 1.79 - 1.81 |
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Tue, 04 Nov 2025
Bluejay Diagnostics Inc. (BJDX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Tue, 14 Oct 2025
Bluejay Diagnostics Raises $4M in Private Placement - TipRanks
Fri, 10 Oct 2025
Bluejay Diagnostics closes $4.5 million private placement - Investing.com
Fri, 10 Oct 2025
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Thu, 09 Oct 2025
Bluejay Diagnostics Shares Skyrocket After Strengthening Manufacturing Deal with SanyoSeiko - MSN
Thu, 09 Oct 2025
$4.5M raise: Bluejay Diagnostics secures private placement to fund FDA approval work - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 382 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | 499.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.7 % |
| Return on Equity (ttm) | -96.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|